Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | basic transcription factor 3b, putative | 0.003 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0405 | 0.4904 | 1 |
Trypanosoma cruzi | transcription factor btf3, putative | 0.003 | 0 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.0233 | 0.2663 | 0.543 |
Toxoplasma gondii | NAC domain-containing protein | 0.003 | 0 | 0.5 |
Leishmania major | basic transcription factor 3a, putative | 0.003 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0794 | 1 | 1 |
Trichomonas vaginalis | serine threonine-protein kinase, putative | 0.0405 | 0.4904 | 1 |
Echinococcus granulosus | serine:threonine protein kinase:endoribonuclease | 0.0794 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0794 | 1 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase:endoribonuclease | 0.0794 | 1 | 1 |
Loa Loa (eye worm) | glutaminase | 0.0233 | 0.2663 | 0.2663 |
Plasmodium vivax | basic transcription factor 3b, putative | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | glutaminase 2 | 0.0233 | 0.2663 | 0.2663 |
Loa Loa (eye worm) | IRE protein kinase | 0.0794 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0407 | 0.4937 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0233 | 0.2663 | 0.5 |
Trypanosoma cruzi | transcription factor btf3, putative | 0.003 | 0 | 0.5 |
Brugia malayi | glutaminase DH11.1 | 0.0233 | 0.2663 | 0.2663 |
Trypanosoma brucei | transcription factor BTF3, putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | glutaminase | 0.0233 | 0.2663 | 0.5394 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -7.612 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.502 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.454 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.316 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.296 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.144 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.064 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.